- Home
- PASG vs CCEL Comparison
PASG vs CCEL Comparison
Compare PASG & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 32.7M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PASG | CCEL |
|---|---|---|
| Price | $9.35 | $3.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 31.2K | 12.5K |
| Earning Date | 04-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.41% |
| EPS Growth | 42.47 | ★ 104.39 |
| EPS | N/A | ★ 0.17 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.03 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.28 | $3.10 |
| 52 Week High | $20.00 | $8.00 |
Technical Indicators
Market Signals| Indicator | PASG | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 47.94 |
| Support Level | $6.31 | $3.33 |
| Resistance Level | $10.71 | $3.57 |
| Average True Range (ATR) | 0.99 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.33 | 62.42 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.